How to Cite
Abstract
Pleural mesothelioma (MP) remains an aggressive disease with a poor prognosis and a median survival of no more than 18-20 months, despite the use of all current treatment approaches. Radiation therapy for MP is traditionally used as a part of a three-modal approach in radical treatment. The lack of reliable randomized trials has led to an absence of consensus of the optimal radical treatment strategy and current guidelines for the MP treatment are quite contradictory regarding the use of radiotherapy. A literature based on the MedLine database, Web of Science was analyzed. Our own experience in multimodal treatment of 8 patients with MP based on retrospective data demonstrates low local control in the irradiated area: 4 patients had isolated local relapse during 1 year; 4 patients had local relapse in combination with distant progression. Univariate analysis had not revealed predictors of isolated local progression after adjuvant radiation therapy in multimodal treatment. Although the role of radiotherapy in the treatment of MP remains unclear, significant successes in planning and conducting of radiation therapy show, that long-term survival now can be achieved for these patients, for whom, until recently, only palliative treatment had been considered appropriate.References
Bakker Е., Guazzelli A., Krstic-Demonacos M. et al. Current and prospective pharmacotherapies for the treatment of pleural mesothelioma // Expert Opin Orphan Drugs. - 2017. - Vol. 5. - P. 455-465. - https://doi.org/10. 1080/21678707.2017.1325358.
Murayama T., Takahashi K., Natori Y, Kurumatani N. Estimation of future mortality from flexural malignant mesothelioma in Japan based on an age-cohort model // Am J. Ind. Med. - 2006. - Vol. 49(1). - P. 1-7. - https://doi.org/10.1002/ajim.20246.
Antman K.H., Blum R.H., Greenberger J.S. et al. Multimodality therapy for malignant mesothelioma based on a study of natural history // Am J Med. - 1980. - Vol. 68. - P. 356-362. - https://doi.org/10.1016/0002-9343(80)90103-5.
Baas P., Fennell D., Kerr K.M. et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. - 2015. - Vol. 26(5). - P. 31-39. - https://doi. org/10.1093/annonc/mdv199.
Scherpereel A., Astoul P., Baas P. et al. Guidelines of the European Respiratory society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma // Eur Respir J. - 2010. - Vol. 35(3). - P. 479-495. - https://doi. org/10.1183/09031936.00063109.
Woolhouse I., Bishop L., Darlison L. et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma // Thorax. - 2018. - Vol. 73(1). - P. 1-30. - https://doi.org/10.1136/ thoraxjnl-2017-211321.
Kindler H.L., Ismaila N., Armato S.G. et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline // J Clin Oncol. - 2018. - Vol. 36(13). - P. 1343-7133. - https://doi.org/10.1200/JCO.2017.76.6394.
Mychalczak B., Nori D., Armstrong J.G. et al. Results of treatment of malignant pleural mesothelioma with surgery, brachytherapy and external beam irradiation // Endocurie Hypertherm Oncol. - 1989. - Vol. 5. - P. 245.
Baldini E.H., Recht A., Strauss G.M. et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma // Ann Thorac Surg. - 1997. - Vol. 63(2). - P. 334-338. - https://doi.org/10.1016/ s0003-4975(96)01228-3.
Allen A.M., Den R., Wong J.S. et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy // Int J Radiat Oncol Biol Phys. - 2007. - Vol. 68(5). - P. 1366-1374. -https://doi.org/ 10.1016/j. ijrobp.2007.02.047.
Krayenbuehl J., Oertel S., Davis J.B., Ciernik I.F. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy // Int J Radiat Oncol Biol Phys. - 2007. - Vol. 69(5). - P. 1593-1599. - https://doi.org/10.1016Zj.ijrobp.2007.07.2370.
Ahamad A., Stevens C.W., Smythe W.R. et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest // Cancer J. - 2003. - Vol. 9(6). - P. 476-484. - https://doi.org/10.1097/00130404- 200311000-00008.
Rice D.C., Smythe W.R., Liao Z. et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma // International Journal of Radiation Oncology Biology Physics. - 2007. - Vol. 69(2). - P. 350-735. -https:// doi.org/10.1016/j.ijrobp.2007.03.011.
Allen A.M., Czerminska M., Janne P.A. et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma // Int J Radiat Oncol Biol Phys. - 2006. - Vol. 65(3). - P. 640-645. - https:// doi.org/10.1016/j.ijrobp.2006.03.012.
Miles E.F., Larrier N.A., Kelsey C.R. et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience // Int J Radiat Oncol Biol Phys. - 2008. - Vol. 71(4). - P. 1143-1150. - https://doi. org/10.1016/j.ijrobp.2007.11.011.
Lewis G.D., Dalwadi S.M., Farach A., Butler B. The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma // Ann Surg Oncol. - 2019. - Vol. 26(6). - P. 1879-1885. - https://doi.org/10.1245/ s10434-019-07235-9.
Nelson D.B., Rice D.C., Niu J. et al. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis // J Clin Oncol. - 2017. - Vol. 35(29). - P. 3354-3362. - https://doi.org/10.1200/ JCO.2017.73.8401.
Nelson D.B., Rice D.C., Mitchell K.G., Tsao A.S. Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database // J Thorac Dis. - 2019. - Vol. 11(4). - P. 1269-1278. - https:// doi.org/10.21037/jtd.2019.04.27.
Stahel R.A, Riesterer O., Xyrafas A. et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial // Lancet Oncol. - 2015. -Vol. 16(16). - P. 1651-1658. - https://doi.org/10.1016/S 1470-2045(15)00208-9.
Rimner A., Simone C.B., Zauderer M.G. et al. Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? // Lancet Oncol. - 2016. - Vol. 17(2). -P. 43-44. - https://doi.org/10.1016/S1470-2045(16)00024-3.
Treasure T., Lang-Lazdunski L., Waller D., et al. Extrapleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study // Lancet Oncol. - 2011. - Vol. 12(8). - P. 763-772. - https://doi. org/10.1016/S 1470-2045(11)70149-8.
Rosenzweig K.E., Zauderer M.G., Laser B. et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma // Int J Radiat Oncol Biol Phys. - 2012. - Vol. 83(4). - P. 12781283. - https://doi.org/10.1016/j.ijrobp.2011.09.027.
Rimner A., Spratt D.E., Zauderer M.G. et al. Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma // Int J Radiat Oncol Biol Phys. - 2014. - Vol. 90(2). - P. 394-401. - https://doi.org/10.1016/j. ijrobp.2014.05.032.
Rimner A., Zauderer M.G., Gomez D.R. et al. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients with Malignant Pleural Mesothelioma // J Clin Oncol. - 2016. - Vol. 34(23). -P. 2761-8. - https://doi.org/10.1200/JCO.2016.67.2675.
MacRae R.M., Ashton M., Lauk O. et al. The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group // Lung Cancer. - 2019. - Vol. 132. - P. 24-27. - https://doi.org/10.1016/j. lungcan.2019.03.023.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020